The Test: Whole genome sequencing to screen for 400+ actionable conditions + processing by Broad Clinical Labs (CLIA/CAP accredited)
Cutting-edge genomics deliver actionable insights for childhood-onset genetic conditions.
Cutting-edge genomics deliver actionable insights for childhood-onset genetic conditions.
The Support: Genetic counseling & care plans for parents + peer-to-peer consults with providers
The Future: Continued access to a child’s genomic profile
The Test: Whole genome sequencing to screen for 400+ actionable conditions + processing by Broad Clinical Labs (CLIA/CAP accredited).
The Support: Genetic counseling & care plans for parents + peer-to-peer consults with providers
The Future: Continued access to a child’s genomic profile
HOW WE COLLABORATE
Scientifically driven. Medically actionable.
We make it easy to integrate newborn genomic screening into your pediatric care. Reporting includes clear, evidence-based insights and recommendations. You get access to our expert medical team of genetic counselors, clinical geneticists, and physicians who can discuss patient cases, interpret results, and provide condition-specific next steps. Connect with our Pediatric Medical Director to learn more about Nurture's seamless integration with your practice.
HOW WE COLLABORATE
Scientifically Driven.
Medically Actionable.
We make it easy to integrate newborn genomic screening into your pediatric care. Reporting includes clear, evidence-based insights and recommendations. You get access to our expert medical team of genetic counselors, clinical geneticists, and physicians who can discuss patient cases, interpret results, and provide condition-specific next steps. Connect with our Pediatric Medical Director to learn more about Nurture's seamless integration with your practice.
Nurture is …
- For healthy (or presymptomatic) children
- Expanding on newborn screening
- Parent initiated & physician authorized
Nurture is not …
- An indication-based test
- A one-time screen
- A final diagnosis
Nurture is …
- For healthy (or presymptomatic) children
- Expanding on newborn screening
- Parent initiated & physician authorized
Nurture is not …
- An indication-based test
- A one-time screen
- A final diagnosis
Today's standard is not meeting the current need.
With 6,000 rare diseases affecting over 20 million Americans, it’s time to widen our lens and be as proactive as possible.3.
5 to 7 years is the average time for rare disease patients to complete their diagnostic journey.6.
80 percent of rare diseases are genetic, with heritable markers detectable at birth.7.
State newborn screening programs have transformed the patient experience for certain diseases, like phenylketonuria (PKU). Our genetic scientists and pediatric rare disease specialists identified hundreds of additional conditions where identification impacts clinical management and where early treatment can change the course of the disease.
Explore Our Conditions List
Today's standard is not meeting the current need.
With 6,000 rare diseases affecting over 20 million Americans, it’s time to widen our lens and be as proactive as possible.3.
5 to 7 years is the average time for rare disease patients to complete their diagnostic journey.6.
80 percent of rare diseases are genetic, with heritable markers detectable at birth.7.
State newborn screening programs have transformed the patient experience for certain diseases, like phenylketonuria (PKU). Our genetic scientists and pediatric rare disease specialists identified hundreds of additional conditions where identification impacts clinical management and where early treatment can change the course of the disease.
Explore Our Conditions ListWHY IT MATTERS
New treatments outpace current screening.
Rare disease research and development have yielded hundreds of new therapies in the last decade. But the breadth of conditions screened for largely remains the same. Some examples include:
Condition: Molybdenum cofactor deficiency (MOCS1)
Treatment: Medication
Impact: Stops intractable seizures, prolongs life
Condition: Metachromatic leukodystrophy (ARSA)
Treatment: Stem cell transplant
Impact: Prevents neuroregression
Condition: Duchenne muscular atrophy (DMD)
Treatment: Exon-skipping therapies
Impact: Improves muscle mass, prolongs life
Condition: Ornithnine transcarbamylase deficiency (OTC)
Treatment: Diet
Impact: Prevents deadly hyperammonemic crises
WHY IT MATTERS
New treatments outpace current screening.
Rare disease research and development have yielded hundreds of new therapies in the last decade. But the breadth of conditions screened for largely remains the same. Some examples include:
Condition: Molybdenum cofactor deficiency (MOCS1)
Treatment: Medication
Impact: Stops intractable seizures, prolongs life
Condition: Metachromatic leukodystrophy (ARSA)
Treatment: Stem cell transplant
Impact: Prevents neuroregression
Condition: Duchenne muscular atrophy (DMD)
Treatment: Exon-skipping therapies
Impact: Improves muscle mass, prolongs life
Condition: Ornithnine transcarbamylase deficiency (OTC)
Treatment: Diet
Impact: Prevents deadly hyperammonemic crises
INFORMED CONSENT
A well-informed decision.
Nurture’s genomic sequencing identifies several types of genes associated with increased rare disease risk, giving families and providers crucial information shortly after birth. To help families understand both the benefits and limitations of our service, we provide an Informed Consent video alongside our documentation.
INFORMED CONSENT
A well-informed decision.
Nurture’s genomic sequencing identifies several types of genes associated with increased rare disease risk, giving families and providers crucial information shortly after birth. To help families understand both the benefits and limitations of our service, we provide an Informed Consent video alongside our documentation.
Play Video
What Families Learn
Know more about Nurture and the genomic health insights we provide to our members.
Play Video
What Families Learn
Know more about Nurture and the genomic health insights we provide to our members.
